This study of more than 215 U.S. and Canadian hospital executives indicates that improved service quality to patients and enhanced financial performance are the driving forces for hospitals that undertake business process reengineering (BPR) activities. Despite reporting moderate success in achieving organizational objectives through BPR, these executives identified lack of staff cooperation, buy-in, and skill as important factors that derail BPR implementation efforts.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/00004010-199904000-00003 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Why CEOs need advanced education and training for optimizing decisions in the development of innovative medicinal products? justification and recommendation.
Front Pharmacol
December 2024
Charité - Universitätsmedizin Berlin, Institute of Clinical Pharmacology and Toxicology, Berlin, Germany.
Chief executives have been educated and trained how to handle business, to take executive decisions, and take care of financial and human resources in favor of the company they are leading. CEOs (chief executive officers) of innovative pharmaceutical businesses, among others, have only seldomly been trained to understand the immense time periods involved between decisions and their moment of impact, and the skills and languages used by their internal and external R&D (research and development) staff. R&D staff and regulators, however, have undergone full training, and are usually capable of understanding each other across their various specialties (among them compound finding, quality, safety, efficacy, efficiency, risk assessment and management).
View Article and Find Full Text PDFAccelerating biosimilar market access: the case for allowing earlier standing.
J Law Biosci
January 2025
Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, 1620 Tremont St. Suite 3030, Boston, MA 02120, USA.
Biosimilars, which are affordable alternatives to biologic medicines, face delays in market entry due to the current patent litigation framework under the Biologic Price Competition and Innovation Act. Currently, biosimilar manufacturers can only initiate patent litigation to attempt to clear weak and invalid patents after submitting their Biologic License Application to the Food and Drug Administration (FDA), which happens after completing extensive, and costly clinical trials. By contrast, generic drug manufacturers can start litigation earlier due to shorter development times and less stringent clinical requirements, allowing them to launch immediately after the primary patent expires.
View Article and Find Full Text PDFSpray drying of reconstituted skim milk fermented with GG: control of glass transition and stickiness.
Food Sci Biotechnol
January 2025
Food Technology Major, Graduate School of International Agricultural Technology, Seoul National University, Pyeongchang, 25354 Republic of Korea.
The effects of glass transition and stickiness on the direct spray drying of reconstituted skim milk (RSM) fermented with GG (LGG) were investigated. The fermented RSM did not spray dry properly due to severe wall depositions; however, it dried well (comparable to the control; RSM with resuspended LGG cells) when skim milk powder (SMP) was added. Adding SMP significantly increased the glass transition and sticky point temperatures of spray-dried powder, ranging from 18.
View Article and Find Full Text PDFBalancing choice and socioeconomic realities: analyzing behavioral and economic factors in social oocyte cryopreservation decisions.
Front Endocrinol (Lausanne)
December 2024
Department of Economics and Business Administration, Ariel University, Ariel, Israel.
Purpose: This research investigates the influence of personal income, the likelihood of pregnancy from cryopreserved oocytes, and the risk of infertility, on the decision-making process of women. The study employs the economic stated preference framework alongside the Theory of Planned Behavior in order to comprehend the process of decision-making.
Design/methodology/approach: The data had been collected from women between the ages of 18 and 65 via questionnaire employing conjoint analysis (CA).
Recent advances in L-Asparaginase enzyme production and formulation development for acrylamide reduction during food processing.
Food Chem X
January 2025
Infection and Epigenetics Laboratory, School of Biotechnology, Kalinga Institute of Industrial Technology, Bhubaneswar 751024, Odisha, India.
L-asparagine is an essential amino acid for cell growth and common constituent of all the proteins. During high temperature food processing it reacts with reducing sugars and leads to acrylamide production through a complex process known as Maillard reaction. L-asparaginase hydrolyses the amine-group of L-asparagine to produce aspartic acid and ammonia.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!